AP2006003842A0 - Kynurenic acid amide derivatives as NR2B receptor antagonists - Google Patents
Kynurenic acid amide derivatives as NR2B receptor antagonistsInfo
- Publication number
- AP2006003842A0 AP2006003842A0 AP2006003842A AP2006003842A AP2006003842A0 AP 2006003842 A0 AP2006003842 A0 AP 2006003842A0 AP 2006003842 A AP2006003842 A AP 2006003842A AP 2006003842 A AP2006003842 A AP 2006003842A AP 2006003842 A0 AP2006003842 A0 AP 2006003842A0
- Authority
- AP
- ARIPO
- Prior art keywords
- acid amide
- receptor antagonists
- amide derivatives
- kynurenic acid
- nr2b receptor
- Prior art date
Links
- HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 title 2
- 102000034527 Retinoid X Receptors Human genes 0.000 title 1
- 108010038912 Retinoid X Receptors Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0401525A HU226977B1 (en) | 2004-07-29 | 2004-07-29 | Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them |
PCT/HU2005/000080 WO2006010967A1 (en) | 2004-07-29 | 2005-07-21 | Kynurenic acid amide derivatives as nr2b receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
AP2006003842A0 true AP2006003842A0 (en) | 2006-12-31 |
Family
ID=89985410
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2006003842A AP2006003842A0 (en) | 2004-07-29 | 2005-07-21 | Kynurenic acid amide derivatives as NR2B receptor antagonists |
Country Status (19)
Country | Link |
---|---|
US (1) | US20090012118A1 (zh) |
EP (1) | EP1771436A1 (zh) |
JP (1) | JP2008508250A (zh) |
KR (1) | KR20070043965A (zh) |
CN (1) | CN1989127A (zh) |
AP (1) | AP2006003842A0 (zh) |
AU (1) | AU2005266162A1 (zh) |
BR (1) | BRPI0513912A (zh) |
CA (1) | CA2574167A1 (zh) |
EA (1) | EA011636B1 (zh) |
GE (1) | GEP20084493B (zh) |
HU (1) | HU226977B1 (zh) |
IL (1) | IL179487A0 (zh) |
MA (1) | MA28819B1 (zh) |
MX (1) | MX2007001057A (zh) |
NO (1) | NO20071111L (zh) |
TN (1) | TNSN07015A1 (zh) |
WO (1) | WO2006010967A1 (zh) |
ZA (1) | ZA200700321B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2608476A1 (en) * | 2005-06-28 | 2007-01-04 | Bausch & Lomb Incorporated | Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of gelatinase a in ocular cells |
EP1988077A4 (en) | 2006-02-23 | 2009-09-02 | Shionogi & Co | NUCLEIC HETEROCYCLIC DERIVATIVES SUBSTITUTED BY CYCLIC GROUPS |
US8008253B2 (en) | 2007-07-03 | 2011-08-30 | Andrew Tasker | Treatment for anxiety |
US9051296B2 (en) | 2009-11-16 | 2015-06-09 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as TTX-S blockers |
SG181733A1 (en) * | 2009-12-15 | 2012-07-30 | Neurop Inc | Compounds for the treatment of neurologic disorders |
KR20120123089A (ko) | 2010-02-16 | 2012-11-07 | 화이자 인코포레이티드 | 5-HT₄ 수용체의 부분 효능제인 (R)-4-((4-((4-(테트라히드로푸란-3-일옥시)벤조[d]이속사졸-3-일옥시)메틸)피페리딘-1-일)메틸)테트라히드로-2H-피란-4-올 |
HU230366B1 (hu) * | 2010-06-29 | 2016-03-29 | Szegedi Tudományegyetem | Kinurénsavamid származékok alkalmazása Huntington-kór kezelésére |
ES2627541T3 (es) | 2012-04-20 | 2017-07-28 | Ucb Pharma, S.A. | Métodos para tratar la enfermedad de Parkinson |
HUP1600179A2 (hu) | 2016-03-04 | 2017-09-28 | Univ Szegedi | Új típusú C-3 szubsztituált kinurénsavszármazékok hatékonyabb neuroprotektív aktivitással |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6713490B2 (en) * | 2002-04-26 | 2004-03-30 | Pfizer, Inc. | 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists |
-
2004
- 2004-07-29 HU HU0401525A patent/HU226977B1/hu unknown
-
2005
- 2005-07-21 GE GEAP20059895A patent/GEP20084493B/en unknown
- 2005-07-21 EA EA200700364A patent/EA011636B1/ru not_active IP Right Cessation
- 2005-07-21 US US11/658,690 patent/US20090012118A1/en not_active Abandoned
- 2005-07-21 AP AP2006003842A patent/AP2006003842A0/xx unknown
- 2005-07-21 CA CA002574167A patent/CA2574167A1/en not_active Abandoned
- 2005-07-21 KR KR1020077000265A patent/KR20070043965A/ko not_active Application Discontinuation
- 2005-07-21 JP JP2007523163A patent/JP2008508250A/ja not_active Withdrawn
- 2005-07-21 CN CNA2005800247588A patent/CN1989127A/zh active Pending
- 2005-07-21 EP EP05764169A patent/EP1771436A1/en not_active Withdrawn
- 2005-07-21 MX MX2007001057A patent/MX2007001057A/es not_active Application Discontinuation
- 2005-07-21 BR BRPI0513912-0A patent/BRPI0513912A/pt not_active IP Right Cessation
- 2005-07-21 AU AU2005266162A patent/AU2005266162A1/en not_active Abandoned
- 2005-07-21 WO PCT/HU2005/000080 patent/WO2006010967A1/en active Application Filing
-
2006
- 2006-11-22 IL IL179487A patent/IL179487A0/en unknown
-
2007
- 2007-01-11 ZA ZA200700321A patent/ZA200700321B/en unknown
- 2007-01-17 TN TNP2007000015A patent/TNSN07015A1/en unknown
- 2007-02-22 MA MA29706A patent/MA28819B1/fr unknown
- 2007-02-27 NO NO20071111A patent/NO20071111L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20090012118A1 (en) | 2009-01-08 |
NO20071111L (no) | 2007-02-27 |
CA2574167A1 (en) | 2006-02-02 |
CN1989127A (zh) | 2007-06-27 |
GEP20084493B (en) | 2008-09-25 |
JP2008508250A (ja) | 2008-03-21 |
MX2007001057A (es) | 2007-04-16 |
HU226977B1 (en) | 2010-04-28 |
AU2005266162A1 (en) | 2006-02-02 |
BRPI0513912A (pt) | 2008-05-20 |
WO2006010967A8 (en) | 2007-01-18 |
IL179487A0 (en) | 2007-05-15 |
MA28819B1 (fr) | 2007-08-01 |
KR20070043965A (ko) | 2007-04-26 |
HU0401525D0 (en) | 2004-09-28 |
EA200700364A1 (ru) | 2007-06-29 |
EP1771436A1 (en) | 2007-04-11 |
EA011636B1 (ru) | 2009-04-28 |
TNSN07015A1 (en) | 2008-06-02 |
WO2006010967A1 (en) | 2006-02-02 |
HUP0401525A2 (en) | 2006-11-28 |
ZA200700321B (en) | 2008-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL179487A0 (en) | Kynurenic acid amide derivatives as nr2b receptor antagonists | |
ZA200800320B (en) | Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists | |
EP2099454A4 (en) | AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS | |
EP1915372A4 (en) | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | |
ZA200705085B (en) | 2,3,4,9-Tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists | |
IL178622A0 (en) | Piperazinylpiperidine derivatives as chemokine receptor antagonists | |
AP1983A (en) | Carboxamide derivatives as muscarinic receptor antagonists | |
AP2006003840A0 (en) | Indole-2-carboxamidine derivatives as NMDA receptor antagonists | |
EP1819342A4 (en) | QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS | |
IL171930A0 (en) | Imidazole derivatives as glutamate receptor antagonists | |
IL237513A0 (en) | Piperazindiones as oxytocin receptor antagonists | |
AP2076A (en) | New Heterocyclic carboxylic acid amide derivatives | |
ZA200806065B (en) | Oxazoloisoquinoline derivatives as thrombin receptor antagonists | |
PL1912976T3 (pl) | Pochodne indol-3-ilokarbonylopiperydynobenzoimidazolu jako antagoniści receptora V1a | |
IL205949A0 (en) | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | |
ZA200904479B (en) | Nitroderivatives as angiotensin II receptor antagonists | |
ZA200802339B (en) | Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists | |
EP1750722A4 (en) | NEW LYSOPHOSPHIC ACID RECEPTORSELECTIVE ANTAGONISTS | |
ZA200903496B (en) | Spiro-piperidine derivatives as via receptor antagonists | |
ZA200608369B (en) | Piperazinylpiperidine derivatives as chemokine receptor antagonists | |
ZA200800516B (en) | Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives as V1a receptor antagonists | |
GB0516617D0 (en) | EP2 Receptor antagonists |